BDM-2 is an allosteric inhibitor of HIV-1 integrase (IN) targeting the IN-LEDGF interaction (INLAI) with potent antiretroviral (ARV) activity; it disrupts the interaction between the catalytic core domain of IN (IN-CCD) and the integrase-binding domain of LEDGF/p75 (IBD); it also exhibits IN multimerization-enhancing activity.